VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR2, PDGFRα, PDGFRβ

The vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2), and platelet-derived growth factor receptors (PDGFRα, PDGFRβ) are members of the receptor tyrosine kinase family. These proteins are transmembrane glycoproteins essential for cellular signal transduction pathways that regulate physiological processes including angiogenesis, lymphangiogenesis, cell survival, migration, and differentiation[1][2][3][4]. Dysregulation of these receptors is associated with numerous diseases, especially cancer, cardiovascular disorders, and inflammation[6][7]. Drugs targeting these receptors act by blocking ligand-induced activation and downstream signaling, primarily used to inhibit tumor vascularization and growth.\n\nGrouped as listed, these targets collectively represent the major signaling pathways modulated in anti-angiogenic and anti-proliferative therapies in oncology and related fields[3][7].

Other names

Flt-1Fms-like tyrosine kinase 1KDRFlk-1Flt-4CD140aPDGFR-alphaCD140bPDGFR-beta

Competitive inhibition of ATP binding to kinase domain, ligand (VEGF, FGF, PDGF) blockade, prevention of downstream phosphorylation cascades (MAPK, PI3K pathways), reduced endothelial cell proliferation and migration, and inhibition of neovascularization in tumors and tissues.